Benjamin R Yerxa
CIK 1145910 · President · last filed 2026-07-27
Benjamin R Yerxa is a President who has filed 41 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for IRD, was dated Oct 23, 2026. Across all open-market trades the lifetime net is −$195.2K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ISPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4222 EMPEROR BLVD., STE. 470
DURHAM, NC 27703-8466
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRD | President | 704,106 | $3.32 | $2.34M | -$22.1K | 1 | 2026-07-27 |
| Opus Genetics, Inc. (OCUP) Delisted | President | 711,535 | $1.17 | $832.5K | -$29.3K | 5 | 2026-04-27 |
| Clearside Biomedical, Inc. (CLSD) Delisted | Director | 1,197 | $0.35 | $421 | $10.2K | 5 | 2024-06-21 |
| INSPIRE PHARMACEUTICALS INC (ISPH) Delisted | EVP & Chf, Research & Develop | 53,857 | — | — | -$154.1K | 27 | 2010-05-13 |
Recent Filings
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-23 | IRD | Notice (144) | −33,189 | -$117.4K | EDGAR |
| 2026-07-27 | IRD | Sell (S) | −7,429 | -$22.1K | EDGAR |
| 2026-07-23 | IRD | Notice (144) | −7,429 | -$22.1K | EDGAR |
| 2026-04-27 | Opus Genetics, Inc. (OCUP) Delisted | Sell (S) | −7,470 | -$39.1K | EDGAR |
| 2026-04-23 | IRD | Notice (144) | −7,470 | -$39.1K | EDGAR |
| 2026-01-26 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +400,000 | $0 | EDGAR |
| 2025-10-24 | Opus Genetics, Inc. (OCUP) Delisted | Tax (F) | −23,795 | -$46.4K | EDGAR |
| 2024-11-25 | Opus Genetics, Inc. (OCUP) Delisted | Buy (P) | +10,000 | $9.8K | EDGAR |
| 2024-11-12 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +332,800 | $0 | EDGAR |
| 2024-06-21 | Clearside Biomedical, Inc. (CLSD) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.